{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:31:09Z","timestamp":1747229469248,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00280-019-03925-z","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T02:03:18Z","timestamp":1567476198000},"page":"1017-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the potential for QTc prolongation with avelumab"],"prefix":"10.1007","volume":"84","author":[{"given":"Yulia","family":"Vugmeyster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclseren","family":"G\u00fczel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliessa","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja H.","family":"Loos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"3925_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. \n                    https:\/\/doi.org\/10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"key":"3925_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/15384047.2017.1394552","volume":"18","author":"S Barkdull","year":"2017","unstructured":"Barkdull S, Brownell I (2017) PD-L1 blockade with avelumab: a new paradigm for treating Merkel cell carcinoma. Cancer Biol Ther 18:937\u2013939. \n                    https:\/\/doi.org\/10.1080\/15384047.2017.1394552","journal-title":"Cancer Biol Ther"},{"key":"3925_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-017-0541-9","volume":"10","author":"B Liu","year":"2017","unstructured":"Liu B, Song Y, Liu D (2017) Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol 10:174. \n                    https:\/\/doi.org\/10.1186\/s13045-017-0541-9","journal-title":"J Hematol Oncol"},{"key":"3925_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"CR Heery","year":"2017","unstructured":"Heery CR, O\u2019Sullivan-Coyne G, Madan RA et al (2017) Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587\u2013598. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30239-5","journal-title":"Lancet Oncol"},{"key":"3925_CR5","unstructured":"Bavencio (avelumab) (2019) [package insert]. Rockland, MA: EMD Serono"},{"key":"3925_CR6","unstructured":"Bavencio (avelumab) (2019) [summary of product characteristics]. Darmstadt, Germany: Merck KGaA"},{"key":"3925_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","volume":"18","author":"JL Gulley","year":"2017","unstructured":"Gulley JL, Rajan A, Spigel DR et al (2017) Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18:599\u2013610. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30240-1","journal-title":"Lancet Oncol"},{"key":"3925_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","volume":"6","author":"C Le Tourneau","year":"2018","unstructured":"Le Tourneau C, Hoimes C, Zarwan C et al (2018) Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 6:111. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0424-9","journal-title":"J Immunother Cancer"},{"key":"3925_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-018-0459-y","volume":"7","author":"U Keilholz","year":"2019","unstructured":"Keilholz U, Mehnert JM, Bauer S et al (2019) Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer 7:12. \n                    https:\/\/doi.org\/10.1186\/s40425-018-0459-y","journal-title":"J Immunother Cancer"},{"key":"3925_CR10","first-page":"1041","volume-title":"Handbook of transnational economic governance regimes","author":"J Abraham","year":"2009","unstructured":"Abraham J (2009) The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: Tietje C, Brouder A (eds) Handbook of transnational economic governance regimes. Martinus Nijhoff Publishers, Leiden, pp 1041\u20131053"},{"key":"3925_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/bjp.2008.238","volume":"154","author":"DM Roden","year":"2008","unstructured":"Roden DM (2008) Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 154:1502\u20131507. \n                    https:\/\/doi.org\/10.1038\/bjp.2008.238","journal-title":"Br J Pharmacol"},{"key":"3925_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","volume":"159","author":"CE Pollard","year":"2010","unstructured":"Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin J-P (2010) An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159:12\u201321. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00207.x","journal-title":"Br J Pharmacol"},{"key":"3925_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/157488610789869247","volume":"5","author":"ML Ponte","year":"2010","unstructured":"Ponte ML, Keller GA, Di Girolamo G (2010) Mechanisms of drug induced QT interval prolongation. Curr Drug Saf 5:44\u201353. \n                    https:\/\/doi.org\/10.2174\/157488610789869247","journal-title":"Curr Drug Saf"},{"key":"3925_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vascn.2008.04.001","volume":"58","author":"HM Vargas","year":"2008","unstructured":"Vargas HM, Bass AS, Breidenbach A et al (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58:72\u201376. \n                    https:\/\/doi.org\/10.1016\/j.vascn.2008.04.001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"3925_CR15","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan J, Tao J, Zhai M et al (2018) Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget 9:25738\u201325749. \n                    https:\/\/doi.org\/10.18632\/oncotarget.25008","journal-title":"Oncotarget"},{"key":"3925_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG (2018) Immune Checkpoint Inhibitor-Associated Myocarditis. Oncologist 23:879\u2013886. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"key":"3925_CR17","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G et al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2:e000247. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2017-000247","journal-title":"ESMO Open"},{"key":"3925_CR18","doi-asserted-by":"publisher","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","volume":"6","author":"A Porta-S\u00e1nchez","year":"2017","unstructured":"Porta-S\u00e1nchez A, Gilbert C, Spears D et al (2017) Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 6:e007724. \n                    https:\/\/doi.org\/10.1161\/JAHA.117.007724","journal-title":"J Am Heart Assoc"},{"key":"3925_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45:383\u2013397. \n                    https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3925_CR20","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/annonc\/mdx170","volume":"28","author":"K Chin","year":"2017","unstructured":"Chin K, Chand VK, Nuyten DSA (2017) Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Ann Oncol 28:1658\u20131666. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx170","journal-title":"Ann Oncol"},{"issue":"4","key":"3925_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10120-018-0903-1","volume":"22","author":"T Doi","year":"2019","unstructured":"Doi T, Iwasa S, Muro K et al (2019) Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer 22(4):817\u2013827. \n                    https:\/\/doi.org\/10.1007\/s10120-018-0903-1","journal-title":"Gastric Cancer"},{"key":"3925_CR22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O et al (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374\u20131385. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30364-3","journal-title":"Lancet Oncol"},{"key":"3925_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL, Russell JS, Hamid O et al (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after\u2009\u2265\u20091\u00a0year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6:7. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0310-x","journal-title":"J Immunother Cancer"},{"key":"3925_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/2168479015597729","volume":"50","author":"R Kleiman","year":"2016","unstructured":"Kleiman R, Litwin J, Morganroth J (2016) Benefits of centralized ECG reading in clinical oncology studies. Ther Innov Regul Sci 50:123\u2013129. \n                    https:\/\/doi.org\/10.1177\/2168479015597729","journal-title":"Ther Innov Regul Sci"},{"key":"3925_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jccase.2015.06.002","volume":"12","author":"A Shah","year":"2015","unstructured":"Shah A, Yousuf T, Ziffra J, Zaidi A, Raghuvir R (2015) Diphenhydramine and QT prolongation \u2013 a rare cardiac side effect of a drug used in common practice. J Cardiol Cases 12:126\u2013129. \n                    https:\/\/doi.org\/10.1016\/j.jccase.2015.06.002","journal-title":"J Cardiol Cases"},{"key":"3925_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2146\/ajhp161070","volume":"75","author":"K Li","year":"2018","unstructured":"Li K, Vo K, Lee BK, Addo N, Coralic Z (2018) Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients. Am J Health Syst Pharm 75:276\u2013282. \n                    https:\/\/doi.org\/10.2146\/ajhp161070","journal-title":"Am J Health Syst Pharm"},{"key":"3925_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2125.2008.03327.x","volume":"67","author":"S Fanoe","year":"2009","unstructured":"Fanoe S, Jensen GB, Sj\u00f8gren P, Korsgaard MPG, Grunnel M (2009) Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol 67:172\u2013179. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03327.x","journal-title":"Br J Clin Pharmacol"},{"key":"3925_CR28","doi-asserted-by":"publisher","first-page":"917846","DOI":"10.1155\/2014\/917846","volume":"2014","author":"P Singh","year":"2014","unstructured":"Singh P, Maldonado-Duran JM (2014) Drug-induced QT prolongation as a result of an escitalopram overdose in a patient with previously undiagnosed congenital long QT syndrome. Case Rep Med 2014:917846. \n                    https:\/\/doi.org\/10.1155\/2014\/917846","journal-title":"Case Rep Med"},{"issue":"3","key":"3925_CR29","doi-asserted-by":"publisher","first-page":"e0119551","DOI":"10.1371\/journal.pone.0119551","volume":"10","author":"E Poluzzi","year":"2015","unstructured":"Poluzzi E, Raschi E, Godman B et al (2015) Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across europe. PLoS One 10(3):e0119551. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0119551","journal-title":"PLoS One"},{"key":"3925_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00280-016-2980-3","volume":"77","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Waxman I, Lambert A, Roy A, Darbenzio R (2016) Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab. Cancer Chemother Pharmacol 77:635\u2013641. \n                    https:\/\/doi.org\/10.1007\/s00280-016-2980-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"3925_CR31","unstructured":"Leighton J, Rahman NA, Sridhara R, et al (2016) BLA multidisciplinary review and evaluation: BLA 761049 Bavencio (avelumab). \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761049Orig1s000MultidisciplineR.pdf\n                    \n                  . Accessed May 20 2019"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03925-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:07:05Z","timestamp":1599001625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03925-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3925"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03925-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Vugmeyster declares employment and patents with EMD Serono; H. Dai and M. Hennessy declare employment with EMD Serono; G. G\u00fczel declares employment with Merck KGaA; A.H. Loos declares employment, patents, royalties, stock in, or other intellectual property with Merck KGaA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All studies were conducted in accordance with the Good Clinical Practice guidelines as defined by the International Conference on Harmonisation\u00a0and Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed consent before starting treatment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}